About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, December 19th, 2012

The QualityStocks
Daily Stock List


Lynas Corp. Ltd. (LYSDY)

Pro-Edge reported recently on Lynas Corp. Ltd. (LYSDY), Leeb's Market Forecast, Energy and Capital did earlier, and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.

Based in Sydney, Australia, Lynas Corp. Ltd., together with their subsidiaries, engages in the exploration and development of rare earths deposits and mineral resources. Their corporate strategy is to create a reliable, fully integrated source of Rare Earths from mine through to market, and to become the benchmark for the security of supply and environmental standards in the global Rare Earths industry. Lynas' shares trade on the OTCQX International.
The foundation of Lynas' strategy is Mount Weld in Western Australia, the richest known deposit of Rare Earths in the world, and a state-of-the-art Rare Earths processing plant, the Lynas Advanced Materials Plant (LAMP), currently under construction near Kuantan in Pahang, Malaysia. The Company holds interest in the Mount Weld project. This includes rare earths oxide deposits located to the south of Laverton, Western Australia.

A bankable feasibility study, including pilot plants, was completed on the Rare Earths deposit at Mount Weld. The first mining campaign was completed on time and on budget. Lynas has completed construction of the Mount Weld Concentration Plant and first crushed ore was fed to the ball mill of the Concentration Plant on May 14, 2011. More than 13,000 dry tonnes of concentrate containing more than 4,800 tonnes of REO were bagged ready for export as at the end of June 2012.

The Company is also involved in the planning, design, and construction of the aforementioned advanced materials processing plant for the production and distribution of rare earth oxides in Malaysia. In addition, Lynas has a strategic alliance with Sojitz Corp. for the Lynas Rare Earths project.

Construction of Phase 1 of the LAMP has been completed. At the end of November 2012, Lynas announced that first feed to kiln and commencement of operations are presently underway at LAMP. The Company anticipates a ramp-up period of three to four months until first commercial sales and subsequent cash generation.

Lynas Corp. Ltd. (LYSDY), closed Wednesday's trading session at $0.62, up 0.16%, on 164,815 volume with 38 trades. The average volume for the last 60 days is 113,675 and the stock's 52-week low/high is $0.57/$1.73.

Guardian 8 Holdings (GRDH)

StockOrange reported earlier on Guardian 8 Holdings (GRDH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Guardian 8 Holdings, by way of their wholly owned operating subsidiary, Guardian 8 Corp., is the developer and manufacturer of the G8 Pro V2. This product combines eight non-lethal technologies designed to prevent and protect an individual from aggressors and assailants. It does this while notifying law enforcement or others of the situation. The Company's intention is to market their personal defense device to professional security organizations, individuals, and families. Guardian 8 Holdings has their headquarters in Scottsdale, Arizona, and the Company's shares trade on the OTC Bulletin Board.

The small, user-friendly, hand-held G8 Pro V2 unit integrates an alerting siren, LED strobe light, laser spotter, camera, microphone, emergency notification, and pepper spray. The G8 Pro V2 product emphasizes a 'layered defense' approach to personal protection. This 'layered defense' is for low impact de-escalation, as well as risk mitigation. The G8 ProV2 establishes overlapping protection zones with increasing levels of non-lethal response.

The G8 ProV2 combines a variety of low impact tools to transform a guard's response to threatening situations. The product's inherent risk mitigation capabilities are additionally enhanced through use of the unit's on-board Command Center Communication Link and Incident Recording Capabilities. The G8 ProV2 unit is specialized for professional security; the anticipation is that a consumer model will be released in 2014.

Markets for the G8 ProV2 include Executive Protection; Event Security; Retail Security; Commercial Real Estate Security; Asset Protection; Government Services, and Campus Safety. They also include Transit Security; Leisure & Tourism Security; Hospital Security; Port & Airport Security, and Corporate Security.

This past October, the Guardian 8 Corp. operating subsidiary of Guardian 8 Holdings announced that they received notification on October 17, 2012 from the US Patent & Trademark Office (USPTO) that the design patent application protecting the Company's G8 Pro V2 product was allowed to proceed to issuance upon payment of standard transaction fees. The design patent was the second patent announced by Guardian 8 in October 2012.

Guardian 8 Holdings (GRDH), closed Wednesday's trading session at $0.23, down 23.33%, on 41,864 volume with 4 trades. The average volume for the last 60 days is 3,080 and the stock's 52-week low/high is $0.10/$0.65.

Boston Therapeutics, Inc. (BTHE)

TaglichBrothers and FeedBlitz reported recently on Boston Therapeutics, Inc. (BTHE), Information Solutions Group did earlier, and we choose to report on the Company today, here at the QualityStocks Daily Newsletter.

Boston Therapeutics, Inc. is a leading developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases. The Company's initial product pipeline is focusing on developing and commercializing therapeutic molecules for diabetes. The basis of their products is on a platform of applied complex carbohydrate chemistry in pharmaceutical and Over-the-Counter (OTC) products. The Company's management and advisory team has broad expertise in complex carbohydrate chemistry, manufacturing, regulatory and clinical development. Boston Therapeutics has their headquarters in Manchester, New Hampshire.

Their pipeline includes SUGARDOWN®, a non-systemic chewable complex carbohydrate dietary supplement tablet designed to moderate post-meal blood glucose. Registered with the Food and Drug Administration (FDA), SUGARDOWN® is a tablet that works in the stomach and intestines by blocking the enzymes that break down carbohydrates. Metformin is the most widely prescribed anti-diabetes drug in the world. In October 2012, Boston Therapeutics announced that the FDA approved their petition to file an Abbreviated New Drug Application (ANDA) for a new, chewable tablet formulation of metformin.

The Company's pipeline also includes BTI-7, a new, chewable dose form of the diabetes drug metformin hydrochloride. In addition, their pipeline includes PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation; and IPOXYN™, an injectable anti-necrosis drug specifically designed to treat lower limb ischemia associated with diabetes.

Today, Boston Therapeutics announced that the French East IV Committee of Protection of Persons (Strasbourg) and the Ministry of Health approved the Company's filing to initiate a clinical study of the efficacy and safety of SUGARDOWN®, taken together with a standard meal on post-meal sugar and insulin blood levels in patients with Type ll diabetes that have been treated with metformin. Boston Therapeutics expects similar applications to undergo filing in the U.S., Hong Kong and South Korea in 2013.

The Company's plan is to enroll 24 patients with Type ll diabetes in the French study. They expect to begin recruiting patients in January 2013, with an estimated total duration of six months (2 patients per cycle of 2 weeks).

Boston Therapeutics, Inc. (BTHE), closed Wednesday's session at $0.51, even for the day. The average volume for the last 60 days is 10,388 and the stock's 52-week low/high is $0.25/$1.05.

SafeCode Drug Technologies Corp. (SAFC)

Real Pennies, The Stock Psycho, Top Gun, MyBestStockAlerts, HotShotStocks, Momentum Hunter, Illuminati Stocks, Cash Cow Stocks, Penny Stock Racer, and Blaque Capital Stocks reported recently on SafeCode Drug Technologies Corp. (SAFC), Email Stock Picks, PennyStock MarketBulls, JackpotStock Picks, RagingStock Bull, Xtreme Stock Picks, and PennyStock PayCheck also reported recently on the Company, and we are reporting today, here at the QualityStocks Daily Newsletter.

Listed on the OTC Bulletin Board, SafeCode Drug Technologies Corp. is the developer of a patent-pending voice recognition technology. This technology provides an essential degree of security that can effectively prevent unauthorized administration of a prescription medication. This voice recognition technology reduces the risks of errors during the administration of prescription medications. Founded in 2010, SafeCode Drug Technologies has their corporate headquarters in Jerusalem, Israel.

Earlier this month, SafeCode announced that they identified and are starting to develop the world's first prototype for the Company's next generation application for Drug Safety Administration. The expectation is that the prototype development and the technology application will be completed within 4-6 months. They will subsequently be demonstrated to global major drug container manufacturers for possible adoption to ensure a new generation drug administration safety application.

Yesterday, SafeCode Drug Technologies announced that they approved a share Buyback Program that was authorized by the Board of Directors. The program will begin on January 1 2013; it is expected to last approximately 1-3 months. The shares will be returned to the Treasury of the Company to be used for further issuances for future acquisitions of companies or technology applications in the medical industry. Funding for the acquisition of the shares will be subject to financing from third parties.

Under the program approved by the Board of Directors, SafeCode Drug Technologies has authorization to repurchase up to 1 million of their outstanding shares of common stock at a price up to $0.20 per share on the open market.

Mr. Joel Klopfer, Chief Executive Officer of SafeCode Drug Technologies said, "The repurchase of shares will be returned to treasury and will be used to enable us to acquire additional technologies that augment our existing commercial technology and/or additional drug safety applications in the medical industry, and we will [be] updating our shareholders in the forthcoming weeks of new and exciting news in regards to further acquisitions."

SafeCode Drug Technologies Corp. (SAFC), closed Wednesday's trading session at $0.055, down 3.51%, on 11,800 volume with 4 trades. The average volume for the last 60 days is 57,833 and the stock's 52-week low/high is $0.025/$0.335.

Spectral Capital Corp. (FCCN)

TheSUBWAY, Wall Street Grand, Lebed.biz, BestOtc, DrStockPick, CRWEWallStreet, CRWEPicks, and CRWEFinance reported previously on Spectral Capital Corp. (FCCN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Based in Seattle, Washington, Spectral Capital Corp. acquires and develops natural resources projects around the world. The Company's strategy focuses on three areas. The near term strategy is the acquisition of cash flow producing oil and gas properties; the medium term strategy is the development of a substantial, producing oil and gas asset portfolio; the long-term strategy is large scale natural resources projects for future growth. Spectral Capital additionally has a European office in Switzerland.

Spectral has targeted goals to produce 5,000 barrels per day in production by 1Q 2014. The Company owns 60 percent of the Shamrock oil field; one existing well is in production. They have permitting to drill 7 additional well locations. The field consists of light, sweet crude, which receives a premium price. This field has existing infrastructure, including a road. The property is 258.99 hectares or 2.59 square kilometers. Shamrock is in the Red Earth region of the Province of Alberta, approximately 150 km from Slave Lake, Alberta.

The current producing well on the property is a 1600-meter vertical well. The pay zone for this well is 18 meters in depth. Spectral Capital's partner has operated more than 160 wells and has more than 17 years of industry experience in the Red Earth and Slave Lake region. The Shamrock property has undergone substantial development by Spectral's Canadian partners.

In addition, Spectral has an option in a gold mining property in Kazakhstan (Bayankol River Basin). The Bayankol alluvial deposit is in the extreme southeast of Kazakhstan approximately 380 km from Almaty, within the Raimbek region, and bordered by China to the east and Kyrgyzstan to the south and west. The deposit area occupies the flood plain of the Bayankol River that runs through the area in a south to north direction for more than 50 km from the Tien Shan Mountain range where the source of the gold mineralization is considered to occur.

Spectral Capital Corp. (FCCN), closed Wednesday's trading at $0.36, up 30.91%, on 20,000 volume with 2 trades. The average volume for the last 60 days is 2,520 and the stock's 52-week low/high is $0.21/$0.92.

Health Revenue Assurance Holdings, Inc. (HRAA)

We are highlighting Health Revenue Assurance Holdings, Inc. (HRAA), here at the QualityStocks Daily Newsletter.

Based in Plantation, Florida, Health Revenue Assurance Holdings, Inc. (HRAA) is a provider of revenue integrity solutions for healthcare organizations. The Company's products and services include business intelligence technology solutions, contract coding, billing, coding and compliance audits, education, revenue cycle consulting, physician services and ICD-10 transition services. HRAA improves the healthcare delivery experience for Doctors, Nurses and Patients while assuring the existence of healthcare organizations. 

The Company has been providing Revenue Integrity programs for healthcare organizations nationwide since 2001. Their personnel are healthcare professionals first and consultants second. In 2011, HRAA received recognition by the South Florida Business Journal as one of the Top Ten Best Places To Work.

HRAA has combined their subject expertise with their intellectual property and technology in developing the Visualizer™ Suite.  The design of the Visualizer™ Suite is to meet the emerging need for data analytics associated with the growth strategies that enable the transformations in healthcare.

Included, as a part of the Company's proactive ICD-10 transition services, is their ICDVisualizer™; it further identifies the areas where clients should focus their efforts and allocate their resources. ICDVisualizer™ is an application designed to assist hospitals, providers and other healthcare organizations in understanding the financial and coding impact of the ICD-9 transition to ICD-10. The ICDVisualizer™ assists healthcare leaders with their need to understand the exponential impact of the transition to ICD-10, including workflow, productivity, process changes and documentation and reimbursement risks.  

The Company's Chairman, CEO and Founder Andrea Clark, RHIA, CCS, CPC-H, in October 2012, was awarded the 2012 AHIMA Triumph Awards Mentor of the Year as the candidate that best exemplifies a rare professional who touches lives and launches professionals toward new horizons.

Last month, HRAA announced their financial results for the third quarter and nine months ended September 30, 2012. For the third quarter of 2012, total revenues were $1,985,516, an increase of $1,562,191 or 369 percent, from revenues of $423,325 for the third quarter of 2011. Net loss was $230,149, or $0.01 per basic and diluted share, for the third quarter of 2012, compared to a net loss of $171,167, or $0.01 per basic and diluted share, for the third quarter of 2011.

For the nine months, ended September 30, 2012, total revenues were $3,619,611. This represents an increase of $2,606,333 or 257 percent, from revenues of $1,013,278 for the first nine months of 2011. Net loss was $1,223,737, or $0.04 per basic and diluted share, for the nine months ended September 30, 2012. This is in comparison to a net loss of $108,536 or $0.01 per basic and diluted share, for the same period in 2011.

Health Revenue Assurance Holdings, Inc. (HRAA), closed today's session at $0.30, up 36.36%, on 193,643 volume with 18 trades. The average volume for the last 60 days is 17,993 and the stock's 52-week low/high is $0.10/$0.40.

Thunder Mountain Gold, Inc. (THMG)

FeedBlitz reported previously on Thunder Mountain Gold, Inc. (THMG), and we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Thunder Mountain Gold, Inc. is a junior gold exploration company with corporate headquarters in Boise, Idaho. They hold a 100 percent interest in a number of U.S. gold projects. As a precious metals explorer, the Company is focusing actively and aggressively on developing high-quality precious and base metal projects in North America through acquisition and grass roots exploration.

Their principal assets are The South Mountain Project – a historic former producer of gold, silver, zinc, lead, and copper, located in southern Idaho, just north of the Nevada border, and their Trout Creek Project – a grass roots gold target in the Eureka-Battle Mountain trend of central Nevada, currently under a Joint Exploration Agreement with Newmont Gold. The Company's flagship property is the South Mountain Mine.

Thunder Mountain Gold owns 100 percent of the South Mountain Mine. This project has a land package consisting of approximately 1,200 acres of mostly private land - owned outright and leased. A new gold discovery was revealed during fieldwork at South Mountain in 2009. The Company conducted more exploration on the new discovery to identify further the gold potential of the gold bearing intrusive breccia.

They staked the Trout Creek target in the Reese River Valley region south of Battle Mountain, Lander County, Nevada, in 2007. The target consists of 60 unpatented lode mining claims. It is defined by a regional gravity high-low flexure and by a magnetic anomaly confirmed via a ground magnetic survey initiated by Thunder Mountain during the summer of 2007. Trout Creek is on an important trend with Newmont's Phoenix Mine; the Gold Acres, Pipeline, and Cortez Mine lie to the southeast.

Last week, Thunder Mountain Gold announced that they received approval from the U.S. Mine Safety and Health Administration (MSHA) for their underground exploration and development work at their South Mountain Project Joint Venture called Owyhee Gold Trust LLC (OGT). OGT will immediately proceed with their plans, which will enlarge the underground mine workings in the Laxey (upper) and Sonneman (lower) levels of the mine. In addition, the Company's JV hired Mr. Michael S. Smith, P.E. as Chief Engineer and Project Manager.

Thunder Mountain Gold, Inc. (THMG), closed at $0.10, up 11.11%, on 23,757 volume with 5 trades. The average volume for the last 60 days is 1,612 and the stock's 52-week low/high is $0.06/$0.18.

VSUS Technologies, Inc. (VSUT)

Financial News Media, Investor Ideas, OtcWizard, Orbit Stocks, Center Stage Stocks, Stocktamer, Pennystocktweeters.com, MarketWireStocks, RockingPennyStocks, and SmallCapVoice reported earlier on VSUS Technologies, Inc. (PGSY), and we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Trading on the OTCQB, VSUS Technologies, Inc. is focusing on the acquisition and development of high-quality metallurgical coal properties in the Republic of Colombia. Upon obtaining the necessary financing, the Company plans to have three revenue producing business units in Colombia. These are coal mining, coking oven facilities, and docks, river, and rail transportation along the Magdalena River to export terminals in Colombia. Additionally, VSUS is exploring allegiances with U.S. universities to study capturing Coal Bed Methane (CBM) in Colombia.

VSUS in the United States is based in Canyon Country, California. VSUS in Colombia is based in Bogota. The corporate plan is to have facilities eventually that will include a coal/rock and soil testing lab, conference rooms and office spaces.

VSUS Technologies (with appropriate financing) plans to build or acquire wholly owned river loading facilities on the Magdalena River close to their mines. The coal will be trucked to these river ports, and then barged through the Magdalena River or by rail to terminals in Barranquilla, Santa Marta, or Buenaventura for export. Initially the Company will utilize existing logistics providers while their transportation projects are undergoing development. Upon completion of the rail projects and the "Road to the Sun" project, they will have one of a few metallurgical coalmines in the world with river, rail, and road access to coal export terminals on the Atlantic and Pacific Oceans. 

The Company owns 100 percent of the La Tabaquera mine in Guaduas, Colombia with an estimated 14-17 MM tonnes of reserves - 70 percent metallurgical and 30 percent thermal coal. The Town of Guaduas is a municipality of 35,000 people with excellent electrical and water supply and an ample workforce. VSUS Technologies will implement new U.S. mining technologies to provide innovative approaches to geological engineering, and clean coal mining in Colombia.

Today, VSUS Technologies announced that on December 13, 2012 they registered a PTO (Programa de Trabajo y Obras), or Works Programme with the Agencia Nacional de Mineria of Colombia for the Company's wholly owned coal Concession Contract #ILE-09551 (registered document number: 2012-14-11180). The National Mining Agency typically approves the PTO within 30-60 days. The programme identifies 5 coal seams. Three are 80 cm thick with an estimated 4.5 Million tonnes of coal; two are 160 cm thick with an estimated 10 Million tonnes of mostly metallurgical coal. VSUS is developing their Environmental Impact Assessment (EIA) and expects to file it soon.

VSUS Technologies, Inc. (VSUT), closed Wednesday's trading session at $0.0098, down 18.33%, on 212,889 volume with 9 trades. The average volume for the last 60 days is 538,078 and the stock's 52-week low/high is $0.0015/$0.15.


The QualityStocks
Company Corner


Bergamo Acquisition Corp. (BGMO)

The QualityStocks Daily Newsletter would like to spotlight Bergamo Acquisition Corp. (BGMO). Today, Bergamo Acquisition Corp. closed trading at $0.0294, up 17.60%, on 1,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 385,709, and its 52-week low/high is $0.01/$0.07.

Bergamo Acquisition Corp. (BGMO) is a global investor targeting a diversified portfolio of large corporate and middle-market companies for sole acquisition and co-investment alongside other sophisticated investors such as private equity funds, hedge funds, investment banks, and other institutions. The company has engaged investments in financial instruments and companies worldwide.

Alternative energy is a key focus of the company. Bergamo Acquisition has developed solar generators for cell phone towers, solar generators for home and industry applications, and solar operated tube well water pumping systems to meet the vast needs of emerging markets. The company’s turnkey solutions help developers, utilities, water districts, power plant owners, and industrial customers diversify their existing generation portfolio.

Bergamo Acquisition executes energy projects from concept through completion, offering design, construction management, and facility maintenance services. Together with pre-designed and packaged Balance of Plant and standardized Power Plant Control Modules, the company enables rapid project commissioning and provides an optimum balance between capital cost, plant performance, and operational and maintenance expenses.

The company’s technical team has been working with government officials, manufactures, and importers in Asia, Africa, and the Middle East to introduce its state-of-the-art technology. Investable funds are already in place to pursue investment opportunities in these and other countries. Bergamo Acquisition relies on its extensive network within the global institutional investment and banking industries to source the best opportunities. Disclaimer

Bergamo Acquisition Corp. Company Blog

Bergamo Acquisition Corp. News:

Bergamo Acquisition Achieves Current Information Status on OTC Markets

Bergamo Acquisition’s CEO Does Radio Interview - Provides Update

Bergamo Acquisition Updates Financials

The Guitammer Company Inc. (GTMM)

The QualityStocks Daily Newsletter would like to spotlight The Guitammer Company Inc. (GTMM). Today, The Guitammer Company Inc. closed trading at $0.15, off by 15.38%, on 5,100 volume with 2 trades. The stock’s average daily volume over the past 60 days is 13,787, and its 52-week low/high is $0.082/$0.35.

The Guitammer Company Inc. (GTMM) is a leader in low-frequency sound products and technology. The company’s award-winning line of patented ButtKicker brand audio transducers let users actually feel the excitement, impacts, special effects, and bone-rattling bass brought by its immersive “4D” patent-protected technology. Guitammer’s products are well known for being musically accurate, powerful, and virtually indestructible.

The Guitammer Company was founded in 1990 by Ken McCaw, an accomplished musician, composer, and producer. Joining forces with Marvin Clamme, former sound engineer for Tom Jones and Merle Haggard, Ken and Marvin developed the original ButtKicker transducer prototypes in 1994.

Today, the ButtKicker brand products are used around the world by leading entertainment and theater companies, including AMC, IMAX, and Disney, in movie theaters and attractions. 85 entertainment locations in 11 countries have incorporated ButtKicker products to-date, providing the ultimate experience to over 10,000 seats. The products are also used in home theaters, simulators, and car audio applications.

Guitammer’s technology is compatible to virtually any digital source, including cable, satellite, fiber optic, IPTV, “over-the-air” broadcast, video games, and audio CDs. The ButtKicker brand products add unparalleled realism and excitement to movies, music, and games. Guitammer’s low-frequency, high-impact sound innovation is the next logical step after HDTV, 3DTV, and TiVo, bringing ground-breaking changes in how consumers enjoy their entertainment. Disclaimer

The Guitammer Company Inc. Company Blog

The Guitammer Company Inc. News:

Guitammer Insiders Acquire An Aggregate Of 156,000 GTMM Shares In Open Market Purchases

Guitammer Third Quarter Revenue More Than Triples To $555,000

Guitammer CEO Mark Luden to Present at 7th Annual Singular Research 'Best of the Uncovereds' Conference in Los Angeles

GlobalWise Investments, Inc. (GWIV)

The QualityStocks Daily Newsletter would like to spotlight GlobalWise Investments, Inc. (GWIV). Today, GlobalWise Investments, Inc. closed trading at $0.40, up 14.29%, on 191 volume with 1 trade. The stock’s average daily volume over the past 60 days is 9,696, and its 52-week low/high is $0.18/$1.87.

GlobalWise Investments, Inc. (GWIV), via wholly-owned subsidiary Intellinetics, Inc., is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. The ECM industry continues to grow rapidly as a result of unrestricted proliferation of digital content within today's business environment. Leveraging its proprietary cloud-based computing software, GlobalWise is poised to capture a significant market share of this burgeoning industry.

GlobalWise's ECM service is delivered to customers via five unique delivery models which cover the spectrum of business needs: Cloud/Saas (Software as a Service), Hardware Vendor Integrated Service, Software Vendor Integrated Service, Premise (Client-Server), Hybrid (Premise & Cloud/Saas).This diversity gives advanced security & privacy features with an on-demand structure needed for large Tier 3 and Tier 4 businesses that are currently underserved by the market.

The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization & automated content management with an open and service-oriented architecture using web services. The company provides strategies, tactics, and technologies used to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full time employee.

GlobalWise's management boasts a combined total of over 60 years in ECM leadership and industry experience. The ECM industry is expected to exceed $5.1 billion by 2013 with Gartner predicting a compound annual growth rate of 9.5%. IBM Market Insights predicts adoption of cloud computing to grow by 26% CAGR between 2010 through 2013. Leveraging management and key department heads, Intellinetics has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry. Disclaimer

GlobalWise Investments Company Blog

GlobalWise Investments News:

GlobalWise Announces Board Changes

GlobalWise Channel Partner Sycle.net Continues to Deliver New Clients

GlobalWise Reports Third Quarter 2012 Financial Results and Provides Revised Fiscal 2012 Guidance

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.75, up 0.40%, on 1,600 volume with 2 trades. The stock’s average daily volume over the past 60 days is 1,610, and its 52-week low/high is $0.06/$3.15.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

VistaGen's lead drug candidate, AV-101, is in Phase Ib development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system.

Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Therapeutics Becomes Member of Centre for Commercialization of Regenerative Medicine Consortium

VistaGen Therapeutics Enhances Predictive Liver Toxicology and Drug Metabolism Bioassay System -- LiverSafe 3D™

VistaGen Therapeutics and Duke University Announce Heart Tissue Engineering Progress at American Heart Association 2012 Scientific Sessions

The Guitammer Company, Inc. (GTMM) Picks Up Good Vibrations

The power of communication is one of the most dramatic accomplishments of the modern age, transforming, among other things, the way people are entertained. From the earliest sound recordings and motion pictures, with silent movies giving way to sound, black and white giving way to color, followed eventually by wide screen, stereo, and 3D. It’s all about making people feel like they are part of the event, part of the action. One game-changing technology has inevitably made way for another.

The latest revolution comes from an Ohio based company that is changing the way theaters and theater goers around the world experience movies and broadcast events. The Guitammer Company has invented a way to communicate the subtle, and often not-so-subtle, vibrations inherent in a sporting or musical or movie event that make the person feel like they are there, experiencing it live. It’s the sensation that some people attempt to capture by simply turning up the volume to annoyingly high levels, volumes that can even damage hearing.

But the Guitammer technology has nothing to do with volume, using instead ultra-low frequency sound waves that are felt rather than heard. Sound waves are picked up from the recorded event, such as the enhanced sound from a movie, and are converted to low frequency vibrations that shake the theater seat or even home couches, creating an undeniable feeling of being there, part of the action. It’s a technology they’ve already installed in theaters all over the world, with in-home versions also available.

To see Guitammer’s latest home theater specials, visit http://dtg.fm/gtmm-holiday-deals

For more information on the company, visit www.guitammer.com

Excitement at VistaGen Therapeutics (VSTA) Continues to Build

A lot of great things have been happening with VistaGen Therapeutics recently. VistaGen is a California-based biotechnology company actively applying its proprietary human pluripotent stem cell technology to launch a new era of drug rescue, predictive heart and liver toxicology, and drug metabolism screening.

VistaGen’s unique stem cell technology-based Human Clinical Trials in a Test Tube™ platform currently involves controlled differentiation (development) of pluripotent stem cells into mature, functional human heart and liver cells that can then be used to predict early in development whether a drug candidate has potential toxicity problems. Determination of potential heart and liver toxicity early on in the development process, far earlier than standard tests, means that drug candidates have a chance of being modified for a successful outcome long before resources are expended on costly and time-consuming animal and human clinical studies. Many otherwise promising drug candidates have been shelved due to heart or liver toxicity issues that surfaced well into the development process and even after FDA approval, representing major losses for drug companies.

By generating new chemical variants of small molecule drug candidates that have shown promise, but are currently on hold due to heart or liver toxicity issues, VistaGen can effectively rescue substantial prior investment by others in discovery and development of the once-promising drugs, building an exclusive and valuable portfolio of proprietary rejuvenated drug candidates. VistaGen plans to have economic participation rights to all of the drug rescue variants it develops, benefitting its bottom line as well as its shareholders. The tremendous promise of this approach has prompted the company’s CEO, Shawn Singh, to purchase 100,000 additional common stock shares of the company, bringing his total holdings to 252,174 shares.

Other recent developments include the company’s formalized membership in the Toronto-based Centre for Commercialization of Regenerative Medicine’s (CCRM) Industry Consortium. VistaGen aims to expand the commercial applications of their Human Clinical Trials in a Test Tube™ platform by building multi-party collaborations with CCRM and members of its Industry Consortium around drug rescue and regenerative medicine opportunities, including pilot nonclinical programs involving blood, heart, liver, and potentially pancreatic beta islet cells. Speaking of these opportunities, Shawn Singh emphasized that such collaborations have the potential to “transform medicine and accelerate significant advances in human health and wellness that stem cell technologies and regenerative medicine promise.”

In addition, the company had earlier announced the completion of a $3.25 million financing commitment from its largest institutional investor, Platinum Long Term Growth VII, LLC.

For additional information on VistaGen’s stem cell technology and current initiatives, visit www.VistaGen.com

Loans4Less.com, Inc. (LFLS) Makes Mortgage Calculation Easy

Few industries have not been touched by the Web and all of the potentials it represents. In the case of Loans4Less, an expanding online mortgage loan broker dealing with residential mortgages, the Web offers a revolution in the way home buyers can shop for mortgages. Unlike some businesses, including many mortgage and real estate businesses, which simply add a Web front-end to their traditional market presence, Loans4Less has made the Web a foundation for its operations, taking full advantage of the latest online technologies. The company sees this as key to growing a devoted fan base, prospects that will become solid customers as they get drawn into the process, becoming comfortable with the company’s information capabilities and trustworthiness.

A good example is the company’s online mortgage calculator and pre-qualifier that provides an easy, flexible, and confidential way for people to get a clear idea of the true costs and fees associated with a new mortgage. Without entering any personal or contact information, viewers can easily manipulate any combination of variables on sliding scales, and see how each is affected by the other, allowing them to arrive at the perfect combination for their needs. All numbers are automatically adjusted to avoid scenarios that are unsupportable, with variables including:

• Income
• Purchase Price
• Monthly Payment
• Total Loan Amount
• Loan Term
• Interest Rate
• Property Tax
• Property Insurance
• Down Payment
• Loan Origination Fee
• Loan Points

The system even does graphical breakdowns, showing, among other things, how the loan will amortize over time. Not only do such online capabilities attract customers, they also educate prospects in what to expect, making the eventual loan application process go much more smoothly and satisfactorily for everyone involved, something that builds customer loyalty and word-of-mouth market support.

For more information, visit www.Loans4Less.com

GreenHunter Energy, Inc. (GRH) Expands Appalachia Transport Fleet Capacity Ahead of Disposal Upgrades, Adds HAZMAT Certification

GreenHunter Energy today updated markets on the status of their wholly owned GreenHunter Water, LLC subsidiary, reporting that the company has put in orders to expand the size of its trucking fleet serving the unconventional shale operators in the Appalachians (Marcellus and Utica plays in Ohio, Pennsylvania, and West Virginia).

President and COO of GRH, Jonathan Hoopes, commented on the addition of the six new Peterbilt 388 Bobtails (three with 100 bbl vacuum tanks and three with identical tanks certified for HAZMAT), noting that the company is running at full capacity in the region and could really use the new operational muscle. The expansion of the Appalachia truck fleet from a mere five at the outset of 2012, to now 31 transport trucks, is a clear indication of the direction GRH is headed and as more and more regional operators come to know/rely on the exemplary services the company can provide, the fleet will likely expand further.

When you throw in the new GRH disposal facilities slated to come on-line relatively soon, you can see that the company is prepping for increased business volume, balancing out the trucking capacity and disposal capacity ahead of growth perfectly. Today’s announcement is also something of a milestone for regional operations as the company has hitherto lacked certified equipment for handling liquids mixed with hydrocarbons, something which is generally no problem since the vast majority of such hydrocarbon-laced water is usually gravity separated on-site anyways. However, there are some pads in this difficult terrain that don’t have the equipment for this kind of on-site separation and thus GRH can now capture even more market space through the fleet expansion, offering a potentially clutch service to this growing customer-base.

This move basically puts GRH in the oil transport business while riveting on some much-needed capacity in the thriving, hydrocarbon-rich Appalachia region. This region has a solid future for such production, so it makes good sense for the company to be growing their overall infrastructural footprint at this phase. A winning combination of absolutely vital water transport and disposal well services has quickly built up a warm brand identity for the company among sector operators doing difficult work in this difficult region.

In the Appalachians the work is dirty, difficult, and brutal. Companies like GRH, who put the operator’s needs first and have capacity on-site, on time, and ready to go when it’s needed can make a killing here. GreenHunter really has put together an attractive portfolio of Total Water Management Solutions™ for these guys, with several key innovations developed from an operator-centric point of view, like the flexible Frac-Cycle™ system that allows flowback and produced water to be recycled into clean brine or fresh water, their bleeding-edge well head management and compliance solutionRAMCAT™ (Remote Access Management Compliance Asset Tracking), or the company’s latest edition, a completely customizable, 10k plus bbl temporary water storage tank system (complete with robust interlocking steel panels for safe/rapid deployment), the MAG Tank™.

As part of the purchase, GRH has bolstered an existing commercial loan facility with a local bank in the heart of the Appalachians, bumping the window up to $3.3M. GreenHunter expects to take delivery of the new hardware early in 2013 (late January) and will be offering this new capacity to hungry hydrocarbon developers in the region as soon as late Q1.

For more information on GreenHunter Energy, visit www.GreenHunterEnergy.com


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters







Stock Guru

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251